moxifloxacin / dexamethasone

Phase 3Small molecule

FFederal University of São Paulo

moxifloxacin / dexamethasone is one of 59 small molecule programs targeting Conjunctivitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConjunctivitisActive, not recruiting

CataractActive, not recruiting

ConjunctivitisPhase 3

Active, not recruiting

CataractPhase 3

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Phase 3

1 2

Tetracaine Hydrochloride

BBausch Health Americas, Inc.

Phase 3

1 3

Phenylephrine Hcl

Bayer

Phase 3

1 4

KPI-121

KKala Pharmaceuticals, Inc.

Phase 3

1 5

moxifloxacin / dexamethasone

FFederal University of São Paulo

Phase 3

2 6

Idose TR

GGlaukos Corporation

Phase 3

1 7

Zolymbus

AbbVie

Preclinical

—8

Neurontin

VViatris Specialty LLC

Preclinical

3 9

Kenalog

BBassett Healthcare

Preclinical

1 10

Xylocaine

MMEDRx USA, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Cataract

NCT07305987

Clinical

Trials by Indication[1]

Cataract2 trials

Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Postoperative Inflammation in Cataract Surgery

Completed·FFederal University of São Paulo·N/A·NCT00331084·132 enrolled

PRO-232 in Patients Subjected to Cataract Surgery

Recruiting·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT07305987·134 enrolled

Conjunctivitis1 trial

Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis

Completed·FFederal University of São Paulo·Phase 3·NCT00732446·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for moxifloxacin / dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — moxifloxacin / dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for moxifloxacin / dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal University of São Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFederal University of São Paulo

moxifloxacin / dexamethasone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Cataract2 trials

Conjunctivitis1 trial

References

Drug Info

Quick Facts

Related News